Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma.
Seki T, Yanaihara N, Shapiro JS, Saito M, Tabata J, Yokomizo R, Noguchi D, Kuroda T, Kawabata A, Suzuki J, Takahashi K, Matsuzawa H, Miyake M, Takenaka M, Iida Y, Yanagida S, Okamoto A. Seki T, et al. Among authors: suzuki j. Sci Rep. 2021 Apr 8;11(1):7689. doi: 10.1038/s41598-021-86913-9. Sci Rep. 2021. PMID: 33833265 Free PMC article.
Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.
Suzuki K, Takakura S, Saito M, Morikawa A, Suzuki J, Takahashi K, Nagata C, Yanaihara N, Tanabe H, Okamoto A. Suzuki K, et al. Among authors: suzuki j. Int J Gynecol Cancer. 2014 Sep;24(7):1181-9. doi: 10.1097/IGC.0000000000000178. Int J Gynecol Cancer. 2014. PMID: 25010038
Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
Ito K, Nakagawa M, Shimokawa M, Hori K, Tashima L, Goto M, Yanagida S, Suzuki J, Kaya R, Kawabata A, Yamada K, Park J, Nasu H, Nishio S, Kondo E, Kaneda M, Tsubamoto H, Arakawa A, Nagasawa T, Motohashi T. Ito K, et al. Among authors: suzuki j. Anticancer Drugs. 2023 Aug 1;34(7):857-865. doi: 10.1097/CAD.0000000000001472. Epub 2022 Dec 5. Anticancer Drugs. 2023. PMID: 36729915 Clinical Trial.
Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis.
Konno Y, Mayama M, Takehara K, Yokoyama Y, Suzuki J, Susumu N, Harano K, Nakagawa S, Nakanishi T, Yamagami W, Yoshihara K, Nomura H, Okamoto A, Aoki D, Watari H. Konno Y, et al. Among authors: suzuki j. J Gynecol Oncol. 2024 Jun 3. doi: 10.3802/jgo.2025.36.e3. Online ahead of print. J Gynecol Oncol. 2024. PMID: 38857908 Free article.
3,184 results